“It is reprehensible that any company would manufacture medicine that could potentially harm children,” the attorney general wrote in a Twitter post. In a statement, Johnson & Johnson said its recalls of medicines, “were precautionary and not undertaken on the basis of any health or safety risks to consumers, and we remain committed to providing consumers with safe and effective over-the-counter medicines.” @ SF Gate
Despite the above, see the house thoughts on JNJ, specifically their oncology pipeline. The most recent earnings call was forward looking and still bedrock despite this fine and the safety risks violated. Johnson and Johnson: Oncology Overview. @HCG Research Associates
More data from @FiercePharma
